ABSI
Price
$9.26
Change
-$0.11 (-1.17%)
Updated
Oct 23, 11:01 AM (EDT)
Capitalization
1.61B
20 days until earnings call
Intraday BUY SELL Signals
CADL
Price
$8.17
Change
-$0.21 (-2.51%)
Updated
Oct 23, 11:04 AM (EDT)
Capitalization
641.23M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABSI vs CADL

ABSI vs CADL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABSI vs. CADL commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Hold and CADL is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABSI with price predictions
Oct 22, 2026

ABSI sees its Stochastic Oscillator ascending out of oversold territory

On October 21, 2026, the Stochastic Oscillator for ABSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In 59 of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ABSI as a result. In 82 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

ABSI moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +17.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 246 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 145 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for ABSI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 23 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.

The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for ABSI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

ABSI broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.533) is normal, around the industry mean (2.973). P/E Ratio (-11.861) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CADL with price predictions
Oct 22, 2026

CADL in -9.70% downward trend, falling for three consecutive days on October 16, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CADL declined for three days, in 242 of 276 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 87 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

CADL moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CADL crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for CADL entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.084) is normal, around the industry mean (2.973). P/E Ratio (-5.701) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ABSICADL
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ABSI: $9.37 vs. CADL: $8.38)
Brand notoriety: ABSI and CADL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABSI: 89% vs. CADL: 58%
Market capitalization -- ABSI: $1.61B vs. CADL: $641.23M
ABSI [@Biotechnology] is valued at $1.61B. CADL’s [@Biotechnology] market capitalization is $641.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABSI’s FA Score shows that 0 FA rating(s) are green while CADL’s FA Score has 1 green FA rating(s).

  • ABSI’s FA Score: 0 green, 5 red.
  • CADL’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABSI and CADL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABSI’s TA Score shows that 5 TA indicator(s) are bullish while CADL’s TA Score has 4 bullish TA indicator(s).

  • ABSI’s TA Score: 5 bullish, 5 bearish.
  • CADL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABSI is a better buy in the short-term than CADL.

Price Growth

ABSI (@Biotechnology) experienced а +5.52% price change this week, while CADL (@Biotechnology) price change was -5.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was -16.50%, and the average quarterly price growth was -16.80%.

Reported Earning Dates

ABSI is expected to report earnings on Nov 12, 2026.

CADL is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABSI
Daily Signal:
Gain/Loss:
CADL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABSI has been loosely correlated with CRSP. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ABSI jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABSI
1D Price
Change %
ABSI100%
-6.67%
CRSP - ABSI
59%
Loosely correlated
-1.01%
RXRX - ABSI
58%
Loosely correlated
-1.65%
ABCL - ABSI
56%
Loosely correlated
-7.11%
BEAM - ABSI
52%
Loosely correlated
-1.13%
SANA - ABSI
49%
Loosely correlated
+0.85%
More

CADL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CADL has been loosely correlated with EDIT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CADL
1D Price
Change %
CADL100%
+0.12%
EDIT - CADL
47%
Loosely correlated
-0.80%
CRSP - CADL
46%
Loosely correlated
-1.01%
SANA - CADL
45%
Loosely correlated
+0.85%
FDMT - CADL
44%
Loosely correlated
-6.10%
RXRX - CADL
44%
Loosely correlated
-1.65%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNSBP23.910.35
+1.49%
MainStreet Bancshares
APAC10.27N/A
N/A
StoneBridge Acquisition II Corp
HCM14.28-0.09
-0.63%
HUTCHMED (China) Limited
MASK0.88-0.03
-3.40%
3 E Network Technology Group Ltd
EMBJ69.21-3.69
-5.06%
Embraer SA